DRONABINOL HEMISUCCINATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C21H30O2.C4H6O4
Molecular Weight	747.0114
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CCC(O)=O.[H][C@@]12CCC(C)=C[C@@]1([H])C3=C(O)C=C(CCCCC)C=C3OC2(C)C.[H][C@@]45CCC(C)=C[C@@]4([H])C6=C(O)C=C(CCCCC)C=C6OC5(C)C

InChI

InChIKey=ZTNSQRHQTPQSCH-VKLRDTKISA-N

InChI=1S/2C21H30O2.C4H6O4/c2*1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15;5-3(6)1-2-4(7)8/h2*11-13,16-17,22H,5-10H2,1-4H3;1-2H2,(H,5,6)(H,7,8)/t2*16-,17-;/m11./s1

HIDE SMILES / InChI

Molecular Formula	C21H30O2
Molecular Weight	314.4617
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C4H6O4
Molecular Weight	118.088
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018651s025s026lbl.pdf
Curator's Comment: description was created based on several sources, including http://www.who.int/medicines/areas/quality_safety/4.2DronabinolCritReview.pdf

Dronabinol also known as (−)-trans-delta9-tetrahydrocannabinol is an active ingredient of cannabis. The drug was approved by FDA for the treatment of anorexia in patients with AIDS and chemotherapy-induced nausea and vomiting. Dronabinol exerts its action by activating CB1 and CB2 recepors which makes it a CNS active medicine.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cannabinoid receptor 2 27 Target ID: P34972 Gene ID: 1269.0 Gene Symbol: CNR2 Target Organism: Homo sapiens (Human) Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018651s025s026lbl.pdf	Agonist 2678		3.13 nM [Ki]
Cannabinoid receptor 1 30 Target ID: P21554\|\|\|Q5UB37 Gene ID: 1268.0 Gene Symbol: CNR1 Target Organism: Homo sapiens (Human) Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018651s025s026lbl.pdf	Agonist 2678		5.05 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Anorexia in AIDS 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018651s025s026lbl.pdf	Primary	Approved 8429	MARINOL Approved Use MARINOL Capsules is indicated for the treatment of: anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Launch Date 1985
Vomiting in cancer chemotherapy 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018651s025s026lbl.pdf	Secondary	Approved 8429	MARINOL Approved Use MARINOL Capsules is indicated for the treatment of: anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Launch Date 1985
Nausea in cancer chemotherapy 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018651s025s026lbl.pdf	Secondary	Approved 8429	MARINOL Approved Use MARINOL Capsules is indicated for the treatment of: anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Launch Date 1985

C_max

Value	Dose	Analyte	Population
7.88 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf	10 mg 2 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DRONABINOL unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
1.32 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf	2.5 mg 2 times / day multiple, oral dose: 2.5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DRONABINOL unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
2.96 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf	5 mg 2 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DRONABINOL unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

AUC

Value	Dose	Analyte	Population
15.2 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf	10 mg 2 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DRONABINOL unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
2.88 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf	2.5 mg 2 times / day multiple, oral dose: 2.5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DRONABINOL unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
6.16 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf	5 mg 2 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DRONABINOL unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

F_unbound

Value	Dose	Analyte	Population
3% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf	10 mg 2 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DRONABINOL unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
3% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf	2.5 mg 2 times / day multiple, oral dose: 2.5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DRONABINOL unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
3% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf	5 mg 2 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DRONABINOL unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

Doses

Dose	Population	Adverse events
30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	Other AEs: Palpitations, Tachycardia... Other AEs: Palpitations (2.5%) Tachycardia (2.5%) Photophobia (2.5%) Vision blurred (2.5%) Eye irritation (2.5%) Dry mouth (40%) Fatigue (30%) Feeling of relaxation (5%) Hunger (10%) Feeling hot (5%) Thirst (5%) Chills (2.5%) Upper respiratory tract infection (2.5%) Hordeolum (2.5%) Increased appetite (7.5%) Polydipsia (2.5%) Sensation of heaviness (2.5%) Muscle spasms (2.5%) Somnolence (37.5%) Headache (10%) Dizziness (5%) Paraesthesia (2.5%) Dysgeusia (5%) Hypoaesthesia (2.5%) Hypotonia (2.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
2.5 mg 2 times / day multiple, oral Dose: 2.5 mg, 2 times / day Route: oral Route: multiple Dose: 2.5 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01253408	unhealthy n = 10 Health Status: unhealthy Condition: Irritable Bowel Syndrome Population Size: 10 Sources: https://clinicaltrials.gov/ct2/show/NCT01253408	Other AEs: Headache... Other AEs: Headache (below serious, 3 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01253408
20 mg 2 times / day multiple, oral Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00217971	unhealthy n = 79 Health Status: unhealthy Condition: Marijuana Addiction Population Size: 79 Sources: https://clinicaltrials.gov/ct2/show/NCT00217971	Other AEs: Diabetes, Concussion... Other AEs: Diabetes (serious, 1 patient) Concussion (serious, 1 patient) Nausea (below serious, 5 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00217971

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737	substrate 1037

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A1 110		CYP1A1 108

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP1A1 218	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/11245634/ Page: 5.0	likely
CYP1A1 218	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/11245634/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf#page=13 Page: 13.0	yes
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf#page=13 Page: 13.0	yes		yes (pharmacogenomic study) Comment: Published data indicate a 2- to 3-fold higher dronabinol exposure in individuals carrying genetic variants associated with diminished CYP2C9 function Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf#page=13 Page: 13.0

Sourcing

Vendor/Aggregator	ID	URL
Alfa Chemistry	26514	https://www.alfa-chemistry.com/delta9-tetrahydrocannabinol-cas-1972-08-3-item-290835.htm
Aurora Fine Chemicals LLC	A17.878.362	http://online.aurorafinechemicals.com/info?ID=A17.878.362
Avantor Inc	76124-756	https://us.vwr.com/store/product/24885630/clinical-forensic-and-toxicology-standards-delta-9-tetrahydrocannabinol-thc-crm-restek
BOC Sciences	26514	https://www.bocsci.com/product/delta-9-tetrahydrocannabinol-cas-1972-08-3-334884.html
BenchChem	B526632	https://www.benchchem.com/product/b526632
ChemFaces	CFN91898	http://www.chemfaces.com/natural/Delta-9-Tetrahydrocannabinol-CFN91898.html
ChemMol	97900439	http://www.chemmol.com/chemmol/97900439.html
LGC Standards	DRE-A17405100ME-100	https://www.lgcstandards.com/US/en/p/DRE-A17405100ME-100
LGC Standards	DRE-A17405100ME-1000	https://www.lgcstandards.com/US/en/p/DRE-A17405100ME-1000
LGC Standards	LGCAMP1088.00-01	https://www.lgcstandards.com/US/en/p/LGCAMP1088.00-01
LGC Standards	LGCAMP1088.00-02	https://www.lgcstandards.com/US/en/p/LGCAMP1088.00-02
LGC Standards	LGCAMP1088.00-05	https://www.lgcstandards.com/US/en/p/LGCAMP1088.00-05
Sigma-Aldrich	T-005_CERILLIAN	https://www.sigmaaldrich.com/catalog/product/cerillian/t005?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	56296_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/56296?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	94785_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/94785?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	T2386_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/t2386?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1651621_USP	https://www.sigmaaldrich.com/catalog/product/usp/1651621?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S526632	http://www.smolecule.com/products/s526632
THE BioTek	bt-266534	https://www.thebiotek.com/product/inhibitors/bt-266534

PubMed

Title	Date	PubMed
Interaction between delta 9-tetrahydrocannabinol and morphine on the motor activity of mice.	1979 May 25	112635
Identification of endocannabinoids and cannabinoid CB(1) receptor mRNA in the pituitary gland.	1999 Aug	10461028
Acute injection of drugs with low addictive potential (delta(9)-tetrahydrocannabinol, 3,4-methylenedioxymethamphetamine, lysergic acid diamide) causes a much higher c-fos expression in limbic brain areas than highly addicting drugs (cocaine and morphine).	1999 Aug 25	10521585
Cannabinoid CB(1) receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme.	2000 Feb 28	10700552
Cerebellar CB(1) receptor mediation of Delta(9)-THC-induced motor incoordination and its potentiation by ethanol and modulation by the cerebellar adenosinergic A(1) receptor in the mouse.	2000 May 12	10802025
Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use.	2001	11311783
An ab initio theoretical study of the stereoisomers of tetrahydrocannabinols.	2001 Apr	11349815
Tetrahydrocannabinol-induced apoptosis of cultured cortical neurones is associated with cytochrome c release and caspase-3 activation.	2001 Apr	11311898
Cannabinoid antagonists: a treatment in search of an illness.	2001 Apr	11296092
Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed.	2001 Apr 20	11334873
(R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide.	2001 Aug	11498713
Screening method for 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid in urine using hollow fiber membrane solvent microextraction with in-tube derivatization.	2001 Aug 25	11522063
Cannabinoid receptors are absent in insects.	2001 Aug 6	11447587
Cannabinoids of diverse structure inhibit two DOI-induced 5-HT(2A) receptor-mediated behaviors in mice.	2001 Feb	11267636
delta(9)-Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Involvement of CB1 cannabinoid receptor and Raf-1.	2001 Feb	11168391
In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor.	2001 Feb	11160626
[Characteristics of abnormal behavior induced by delta 9-tetrahydrocannabinol in rats].	2001 Jan	11233294
Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance.	2001 Jan	11229617
Separation of cannabinoid receptor affinity and efficacy in delta-8-tetrahydrocannabinol side-chain analogues.	2001 Jan	11159703
Dragon's Blood incense: misbranded as a drug of abuse?	2001 Jan 1	11056265
High rates of midazolam self-administration in squirrel monkeys.	2001 Jul	11548111
Involvement of somatodendritic 5-HT(1A) receptors in Delta(9)-tetrahydrocannabinol-induced hypothermia in the rat.	2001 Jul-Aug	11509221
Activation of type II cannabinoid receptors improves myocardial tolerance to arrhythmogenic effects of coronary occlusion and reperfusion.	2001 Jun	11586395
Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates.	2001 Jun	11465637
Effects of fluvoxamine on ethanol-reinforced behavior in the rat.	2001 Jun	11356922
Cannabinoid-induced alterations in brain disposition of drugs of abuse.	2001 Jun 1	11331071
Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion neurones.	2001 Mar	11226126
Novel pyrazole cannabinoids: insights into CB(1) receptor recognition and activation.	2001 Mar	11181936
Critical role of the endogenous cannabinoid system in mouse pup suckling and growth.	2001 May 11	11426843
Delta9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study.	2001 May 11	11426837
Long term cerebroprotective effects of dexanabinol in a model of focal cerebral ischemia.	2001 May 18	11368967
[Antiarrhythmic properties of a cannabinoid (CB) receptor agonist].	2001 May-Jun	11558437
[Passive exposure in detection of low blood and urine cannabinoid concentrations].	2001 May-Jun	11508050
Cannabinoid-induced motor incoordination through the cerebellar CB(1) receptor in mice.	2001 May-Jun	11420093
Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.	2001 May-Jun	11420092
Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine.	2001 May-Jun	11420084
Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study.	2001 Oct	11599601
Solid-phase extraction and GC-MS analysis of THC-COOH method optimized for a high-throughput forensic drug-testing laboratory.	2001 Oct	11599598
Cannabinoid activity curtails cocaine craving.	2001 Oct	11590424
Electrophysiological evidence of serotonergic impairment in long-term MDMA ("ecstasy") users.	2001 Oct	11579003
Marijuana abstinence effects in marijuana smokers maintained in their home environment.	2001 Oct	11576029
Neuropsychological performance in long-term cannabis users.	2001 Oct	11576028
Ethanol increases plasma Delta(9)-tetrahydrocannabinol (THC) levels and subjective effects after marihuana smoking in human volunteers.	2001 Oct 1	11543984
The psychoactive ingredient of marijuana induces behavioural sensitization.	2001 Sep	11576193
Hu 210: a potent tool for investigations of the cannabinoid system.	2001 Summer	11474421

Patents

Sample Use Guides

In Vivo Use Guide

Appetite Stimulation: Initially, 2.5 mg capsules should be administered orally twice daily, before lunch and supper. For patients unable to tolerate this 5 mg/day dosage, the dosage can be reduced to 2.5 mg/day, administered as a single dose in the evening or at bedtime. Antiemetic: it is best administered at an initial dose of 5 mg/m2, given 1 to 3 hours prior to the administration of chemotherapy, then every 2 to 4 hours after chemotherapy is given, for a total of 4 to 6 doses/day. Should the 5 mg/m2 dose prove to be ineffective, and in the absence of significant side effects, the dose may be escalated by 2.5 mg/m2 increments to a maximum of 15 mg/m2 per dose.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:22:41 GMT 2023` Edited by `admin` on `Fri Dec 15 16:22:41 GMT 2023`
Record UNII	M67MK6J9X0
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DRONABINOL HEMISUCCINATE

Common Name

English

Code System Code Type Description

PUBCHEM

76967311

Created by admin on Fri Dec 15 16:22:41 GMT 2023 , Edited by admin on Fri Dec 15 16:22:41 GMT 2023

PRIMARY

FDA UNII

M67MK6J9X0

Created by admin on Fri Dec 15 16:22:41 GMT 2023 , Edited by admin on Fri Dec 15 16:22:41 GMT 2023

PRIMARY

Related Record Type Details


					7J8897W37S

DRONABINOL

PARENT -> SALT/SOLVATE


					AB6MNQ6J6L

SUCCINIC ACID

PARENT -> SALT/SOLVATE

Related Record Type Details


					7J8897W37S

DRONABINOL

ACTIVE MOIETY

AE	Significance	Dose	Population
Headache	10%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Hunger	10%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Chills	2.5%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Eye irritation	2.5%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Hordeolum	2.5%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Hypoaesthesia	2.5%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Hypotonia	2.5%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Muscle spasms	2.5%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Palpitations	2.5%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Paraesthesia	2.5%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Photophobia	2.5%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Polydipsia	2.5%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Sensation of heaviness	2.5%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Tachycardia	2.5%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Upper respiratory tract infection	2.5%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Vision blurred	2.5%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Fatigue	30%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Somnolence	37.5%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Dry mouth	40%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Dizziness	5%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Dysgeusia	5%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Feeling hot	5%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Feeling of relaxation	5%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Thirst	5%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Increased appetite	7.5%	30 mg 1 times / day single, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40	unhealthy, mean age 36 years n = 40 Health Status: unhealthy Condition: cannabinoid abuse Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Headache	below serious, 3 patients	2.5 mg 2 times / day multiple, oral Dose: 2.5 mg, 2 times / day Route: oral Route: multiple Dose: 2.5 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01253408	unhealthy n = 10 Health Status: unhealthy Condition: Irritable Bowel Syndrome Population Size: 10 Sources: https://clinicaltrials.gov/ct2/show/NCT01253408
Nausea	below serious, 5 patients	20 mg 2 times / day multiple, oral Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00217971	unhealthy n = 79 Health Status: unhealthy Condition: Marijuana Addiction Population Size: 79 Sources: https://clinicaltrials.gov/ct2/show/NCT00217971
Concussion	serious, 1 patient	20 mg 2 times / day multiple, oral Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00217971	unhealthy n = 79 Health Status: unhealthy Condition: Marijuana Addiction Population Size: 79 Sources: https://clinicaltrials.gov/ct2/show/NCT00217971
Diabetes	serious, 1 patient	20 mg 2 times / day multiple, oral Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00217971	unhealthy n = 79 Health Status: unhealthy Condition: Marijuana Addiction Population Size: 79 Sources: https://clinicaltrials.gov/ct2/show/NCT00217971

Details

SMILES

InChI

DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018651s025s026lbl.pdfCurator's Comment: description was created based on several sources, including http://www.who.int/medicines/areas/quality_safety/4.2DronabinolCritReview.pdf

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018651s025s026lbl.pdf
Curator's Comment: description was created based on several sources, including http://www.who.int/medicines/areas/quality_safety/4.2DronabinolCritReview.pdf

C_max

F_unbound

Drug as perpetrator